The purpose of this email is to remind VFC-enrolled providers that the monoclonal antibody product nirsevimab (trade name Beyfortus® manufactured by Sanofi) will be available for ordering on Friday, August 1, 2025.
Download the RSV Vaccine Available for Ordering MemoThe purpose of this memo is to provide VFC- enrolled providers with information on ordering timelines and administration start dates for the maternal RSV vaccine (ABRYSVO®) and the monoclonal antibody nirsevimab (Beyfortus®) for the upcoming season.
We are writing to inform you of several changes to the Vaccines for Children (VFC) program policies that may affect your practice, effective July 1, 2025. These updates pertain to the COVID-19 vaccine recommendations, RSV monoclonal antibody products, private stock vaccine requirements and the definition of underinsured. Please review the information below and reach out with any questions.
Dear Providers,The North Carolina Department of Health and Human Services has launched a new, bilingual Childhood Vaccines Toolkit designed to help health care providers and families start a conversation about childhood vaccines. The toolkit offers clear, accessible resources to ensure parents have the information they need to protect what matters most — their children’s health.
We’re excited to announce our Provider Lunch and Learn series, a new virtual educational offering from the North Carolina Immunization Program (NCIP). These quarterly sessions, held on the 3rd Wednesday of the first month in each quarter, will take a deeper dive into timely and relevant immunization topics.Lunch and Learn sessions are offered in addition to our monthly Provider Webinars, which will continue the first Wednesday of each month.
This email is to inform you that the NC Immunization Program (NCIP) received guidance that the Centers for Disease Control and Prevention (CDC) has released updated versions of the Child and Adolescent and Adult Immunization Schedules, following a directive from the U.S. Secretary of Health and Human Services to revise COVID-19 vaccine recommendations.